Compositions and Methods for Treating Aging-Related Disorders

Abstract

This invention provides a composition comprising at least three agents selected from the group consisting of alpha-ketoglutarate, malate, pterostilbene, micro-dosed lithium, glycine, ginger, Rhodiola rosea, acetyl glucosamine, vitamin C, glucosamine, fisetin, L-theanine, oxaloacetate, fumarate, succinate, hyaluronic acid, butyrate, anthocyanins, piperlongumine, quercetin, curcuminoids, caffeine, trehalose, and spermidine. This invention also provides related pharmaceutical compositions, methods for ameliorating hallmarks of aging, and articles of manufacture.

1 . A composition comprising at least three agents selected from the group consisting of alpha-ketoglutarate, malate, pterostilbene, micro-dosed lithium, glycine, ginger,  Rhodiola rosea , acetyl glucosamine, vitamin C, glucosamine, fisetin, L-theanine, oxaloacetate, fumarate, succinate, hyaluronic acid, butyrate, anthocyanins, piperlongumine, quercetin, curcuminoids, caffeine, trehalose, and spermidine. 
     
     
         2 . The composition of  claim 1 , wherein the composition comprises at least three agents selected from the group consisting of alpha-ketoglutarate, malate, pterostilbene, micro-dosed lithium, glycine, ginger extract,  Rhodiola rosea , acetyl glucosamine, vitamin C, glucosamine, fisetin, and L-theanine. 
     
     
         3 . The composition of  claim 1 , wherein the composition comprises alpha-ketoglutarate, micro-dosed lithium, and fisetin. 
     
     
         4 . The composition of  claim 3 , wherein the composition comprises alpha-ketoglutarate, micro-dosed lithium, fisetin, glycine, and pterostilbene. 
     
     
         5 . The composition of  claim 1 , wherein the composition comprises alpha-ketoglutarate, micro-dosed lithium, fisetin, glycine, pterostilbene and glucosamine. 
     
     
         6 . The composition of  claim 1 , wherein the composition comprises alpha-ketoglutarate, fisetin, pterostilbene, and glycine. 
     
     
         7 . The composition of  claim 6 , wherein the composition comprises alpha-ketoglutarate, fisetin, glycine, pterostilbene, and glucosamine. 
     
     
         8 . The composition of  claim 1 , wherein the composition comprises alpha-ketoglutarate, malate, pterostilbene, micro-dosed lithium, glycine, ginger extract,  Rhodiola rosea , hyaluronic acid, vitamin C, glucosamine, fisetin, and L-theanine. 
     
     
         9 . The composition of  claim 8 , wherein the composition comprises 1,100 mg of calcium alpha-ketoglutarate, 2,000 mg of magnesium malate, 50 mg of pterostilbene, 1 mg of micro-dosed lithium, 2,000 mg of glycine, 80 mg of ginger extract, 300 mg of  Rhodiola rosea,  100 mg of hyaluronic acid, 100 mg of vitamin C, 1,000 mg of glucosamine sulphate, 100 mg of fisetin, and 150 mg of L-theanine. 
     
     
         10 . The composition of  claim 9 , wherein the composition comprises 1,100 mg of calcium alpha-ketoglutarate, 2,000 mg of magnesium malate, 50 mg of pterostilbene, 1 mg of micro-dosed lithium, 2,000 mg of glycine, 80 mg of ginger extract, 300 mg of  Rhodiola rosea,  100 mg of hyaluronic acid, 100 mg of vitamin C, 1,000 mg of glucosamine sulphate, 100 mg of fisetin, 150 mg of L-theanine, xylitol, malic acid, flavoring, silicon dioxide, calcium silicate, and rebaudioside A. 
     
     
         11 . The composition of  claim 1 , wherein one or more of the agents in the composition is formulated for delayed release and/or extended release. 
     
     
         12 . The composition of  claim 11 , wherein the alpha-ketoglutarate, micro-dosed lithium, fisetin, butyrate, pterostilbene, and glycine are formulated for delayed release and/or extended release. 
     
     
         13 . The composition of  claim 11 , wherein each agent is formulated for delayed release and/or extended release. 
     
     
         14 . A composition comprising (i) the composition of  claim 1  and (ii) a pharmaceutically acceptable carrier. 
     
     
         15 . A method for ameliorating at least one aging hallmark in a subject comprising administering to the subject the composition of  claim 1 , wherein the aging hallmark is selected from the group consisting of genomic instability, telomere attrition, an epigenetic alteration, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. 
     
     
         16 . The method of  claim 15 , wherein the method further comprises concurrently administering a nicotinamide-based compound to the subject. 
     
     
         17 . The method of  claim 15 , wherein the method ameliorates genomic instability, telomere attrition, one or more epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. 
     
     
         18 . The method of  claim 15 , wherein the subject is a human. 
     
     
         19 . The method of  claim 15 , wherein the subject is a cat, a dog, or a horse. 
     
     
         20 . An article of manufacture comprising, in separate compartments, (i) the composition of  claim 1  and (ii) a nicotinamide-based compound. 
     
     
         21 . The article of  claim 20 , wherein the article comprises, in separate compartments, (i) a composition comprising alpha-ketoglutarate, malate, pterostilbene, micro-dosed lithium, glycine, ginger extract,  Rhodiola rosea , hyaluronic acid, vitamin C, glucosamine, fisetin, and L-theanine, and (ii) nicotinamide mononucleotide. 
     
     
         22 . The article of  claim 21 , wherein the article comprises, in separate compartments, (i) a composition comprising 1,100 mg of calcium alpha-ketoglutarate, 2,000 mg of magnesium malate, 50 mg of pterostilbene, 1 mg of micro-dosed lithium, 2,000 mg of glycine, 80 mg of ginger extract, 300 mg of  Rhodiola rosea,  100 mg of hyaluronic acid, 100 mg of vitamin C, 1,000 mg of glucosamine sulphate, 100 mg of fisetin, and 150 mg of L-theanine, and (ii) 125 mg of nicotinamide mononucleotide.